Other Information
−Removed: Ocuphire Pharma, Inc.
+Added: During the quarter ended March 31, 2024, none of the Company’s directors or officers has adopted or terminated a Rule 10b5-1
+Added: trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Exchange Act).
DESCRIPTION OF DOCUMENT
−Removed: Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Appendix G to
−Removed: the Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2005).
−Removed: Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by
−Removed: reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on May 5, 2017).
−Removed: Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by
−Removed: reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on August 30, 2018).
−Removed: Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by
−Removed: reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 12, 2019).
−Removed: Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to
−Removed: Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on November 6, 2020).
−Removed: Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to
−Removed: Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed on November 6, 2020).
−Removed: Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the
−Removed: Registrant’s Current Report on Form 8-K, filed on November 6, 2020).
−Removed: First Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to
−Removed: Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 10, 2022).
−Removed: Second Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to
−Removed: Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 17, 2022).
−Removed: Third Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to
−Removed: Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 2, 2023).
−Removed: Purchase Agreement, dated as of August 10, 2023, by and between
−Removed: Ocuphire Pharma, Inc.
−Removed: and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 11, 2023).
−Removed: Registration Rights Agreement, dated as of August 10, 2023, by
−Removed: and between Ocuphire Pharma, Inc.
−Removed: and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on August 11, 2023).
+Added: Third Amendment to the Consulting Agreement, dated as of January 1, 2024, by and between the Company and Jay Pepose, M.D.
+Added: Employment Agreement, dated as of February 13, 2024, by and between the Company and Nirav Jhaveri (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 16, 2024).
+Added: First Amendment to Employment Agreement, dated as of February 16, 2024, by and between the Company and Nirav Jhaveri (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on February 16, 2024).
+Added: Consulting Agreement, dated as of April 11, 2024, by and between the Company and Jay Pepose, M.D.
+Added: (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 17, 2024).
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
Documents are furnished not filed.
+Added: Filed herewith.
Ocuphire Pharma, Inc.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: November 13, 2023
Ocuphire Pharma, Inc.
1 unchanged sentence
George Magrath
−Removed: Chief Executive Officer
+Added: Chief Executive Officer and Director
(Principal Executive Officer)
+Added: /s/ Nirav Jhaveri
+Added: Nirav Jhaveri
+Added: Chief Financial Officer
+Added: (Principal Financial Officer)
/s/ Amy Rabourn
Senior Vice President of Finance
−Removed: (Principal Financial Officer)
+Added: (Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.